GE Healthcare announced today the shipment of the Omnyx™ VL4 scanner to beta customers worldwide. To date, six Omnyx VL4 scanners have been shipped and are in operation for testing purposes. This marks a significant milestone in Omnyx’s efforts to deliver a leading Integrated Digital Pathology solution. The Omnyx solution will be demonstrated at the upcoming Pathology Visions conference in San Diego.
The scanner is tightly integrated to an enterprise software solution that enables high-speed digital viewing over standard networks and provides a complete digital workflow for research use for both the pathologist and histology personnel.
HSD partnered with Omnyx, assisting in Design Research, Industrial Design, GUI, Engineering and prototyping leading to the successful manufacturing launch of the new VL4 scanner.
BioNanomatrix, Inc. has changed its name to BioNano Genomics. By adopting the new name and brand identity, the Company is communicating its position as a solution provider for genomics researchers who want to fully understand the biology of the genomes at the core of their research. The change follows the recent establishment of new corporate headquarters in San Diego, the appointment of new leadership, and additional new investment.
The corporate re-branding reflects the Company’s expanding focus on delivering genomic applications for its nanoAnalyzer System®, a platform that uses single-molecule imaging to visualize extremely long nucleic acids and reveal genome architecture in its native state. BioNano Genomics makes full genome understanding more accessible to researchers and clinicians who seek simpler ways of examining whole genomes while extending their investigations beyond the realm of variation at the level of only a few nucleotides.
BioMarker Strategies was recently awarded an additional NCI SBIR contract to develop companion diagnostic test and raises $2.3M in investments. HS Design was hired by BioMarker Strategies to work on the development of user research, usability, design and development for both the SnapPath™ Platform including the instrument, Graphical user interface (GUI) and injection molded disposable cartridge. The program will see HS Design working with BioMarker Strategies towards the complete development of its benchtop instrument for clinical trials and commercial release. The SnapPath™ biomarker testing system* is an automated live tumor cell processing platform that enables next-generation predictive tests—known as Functional Signaling Profiles (FSPs)—to guide targeted drug therapy selection for individual cancer patients. http://www.genomeweb.com/dxpgx/biomarker-strategies-wins-nci-grant-biomarker-system
HSD recently completed a new program to convert an Apple iPhone 4 & iTouch into a revolutionary new medical device. The DermScope is the world’s first intelligent dermatoscope, designed to address all of the important modes of skin visualization. DermScope helps Doctors to improve their confidence in diagnosis while increasing the efficiency and effectiveness of the exam. Images can be instantly sent across the globe for consult. The injection molded case minimized the external profile giving the unit a simple intuitive feel.